Yale Cancer Center | Strategic Alliance Partners

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center.

Edward Kaftan, PhD, has been appointed Assistant Cancer Center Director for Translational Science at Yale Cancer Center.

Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.

Anne Chiang, MD, PhD, has been named Deputy Chief Medical Officer and Chief Integration Officer at Smilow Cancer Hospital.

January 25, 2021 - Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine.

In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on prostate cancer hosted by Yale Cancer Center.

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Daniel P. Petrylak, MD, highlights the use of abiraterone acetate, enzalutamide, and apalutamide and how these agents can lead to improvements in overall survival and progression-free survival in patients with hormone-sensitive prostate cancer.

Michael E. Hurwitz, MD, PhD, highlights the role of second-generation androgen blockers in nonmetastatic castration-resistant prostate cancer, how these agents compare, and active areas of investigation.

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

December 10, 2020 — Despite gene expression tests helping health care professionals make optimal treatment decisions, testing varies by region for men with prostate cancer and could be related to socioeconomic status and patterns of prostate cancer care.

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Daniel P. Petrylak, MD, discusses the ever-changing prostate cancer armamentarium, as well as the role of biomarkers and new diagnostic methods in the space.

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

The Breast Cancer Research Foundation has awarded a 1-year, $175,000 research grant to Yale Cancer Center to study reducing re-excisions for breast conserving therapy for women following surgery for breast cancer.

Yale Cancer Center researchers were awarded a five-year, $11.7 million grant from the National Institutes of Health to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence.

James B. Yu, MD, MHS, has been promoted to Associate Chief Medical Officer for Radiation Oncology for Smilow Cancer Hospital and Smilow Cancer Hospital Network.

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer. 

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.

In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act a higher percentage of women with breast cancer had their disease diagnosed at an early stage.

Markus Müschen, MD, PhD, has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital.

One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and sometimes be fatal.

Yale Cancer Center researchers were awarded a $2.8 million grant from the National Cancer Institute to evaluate and model cytokine signaling related to immunotherapy for cancer.

Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer.